Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacabrutideg in B-Cell Malignancies
NCT05006716Phase 2Recruiting
- Sponsor
- BeOne Medicines
- Start
- Sep 2021
- Primary completion
- Mar 2027
- Countries
- 16
01
Overview
A Phase 2 trial of tacabrutideg in B-cell malignancy, marginal zone lymphoma (MZL), follicular lymphoma (FL), non-Hodgkin lymphoma (NHL), Waldenström macroglobulinemia (WM), sponsored by BeOne Medicines. Started Sep 2021; status: recruiting.
02
Drugs
tacabrutideg
03
Conditions
B-cell malignancymarginal zone lymphoma (MZL)follicular lymphoma (FL)non-Hodgkin lymphoma (NHL)Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT05006716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05006716.